Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Indian share markets remain volatile
Fri, 8 Feb 01:30 pm

Indian share markets pared gains and hovered around the dotted line in the post noon trading session. Majority of the sectoral indices are trading in the negative with metal, FMCG and realty stocks being the biggest losers. IT, capital goods and consumer durable stocks are among the few stocks trading in the green.

BSE-Sensex is down 4 points and NSE-Nifty is trading down by 7 points. While BSE Mid Cap is down 0.4%, BSE Small Cap index is down by 0.5%. The rupee is trading at 53.5 to the US dollar.

Majority of the auto ancillary stocks are trading in the red with Mahindra Forgings and Sundaram Clayton being the biggest losers. However, Exide Industries and Carborundum Universal are few of the stocks trading in the green. As per a leading financial daily, Bharat Forge is forming a joint-venture company with US-based Elbit Systems Land and C41 Ltd to cater to the country's defence sector. The joint-venture company will offer solutions in the artillery guns and mortar segment by utilizing the US company's technology and system integration capabilities and Bharat Forge's expertise in design, engineering, manufacturing, testing and validation. Apart from Bharat Forge, the Mahindra & Mahindra Group is the other player from the auto industry that is entering the defence sector through tie-ups with overseas companies. Bharat Forge stock is currently down 1.2%.

Most of the pharma stocks are trading in the red with Cipla and Orchid Chemicals leading the losers. Sun Pharma declared its December 2012 quarter results. The topline of the company grew by 34% YoY during the quarter led by growth in its international formulations and API segments. The US and ROW markets witnessed robust growth of above 40% for 3QFY13. Sun Pharma's subsidiary Taro also witnessed healthy growth of 25% YoY. The domestic segment witnessed modest growth of 13% YoY for the quarter, though growth was above the domestic pharma industry growth of 10% YoY during the same period. The operating margins declined marginally by 0.5% and operating profits grew by 32% YoY. The bottomline increased by 32% YoY during 3QFY13, inspite of higher incidence of tax, which grew by 274% YoY.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian share markets remain volatile". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.